![Tomer Yossef](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tomer Yossef
Keine laufenden Positionen mehr
Karriereverlauf von Tomer Yossef
Ehemalige bekannte Positionen von Tomer Yossef
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Direktor/Vorstandsmitglied | 31.07.2018 | - |
Independent Dir/Board Member | 31.07.2018 | - |
Ausbildung von Tomer Yossef
Tel-Aviv University | Graduate Degree |
Statistik
International
Israel | 3 |
Operativ
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Börse
- Insiders
- Tomer Yossef
- Erfahrung